(Q82777810)
English
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study
scientific article published on 01 April 2010
Statements
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study (English)
Joel Kremer
Christopher Ritchlin
Alan Mendelsohn
Daniel Baker
Lilianne Kim
Zhenhua Xu
John Han